Recent Company News

• 06:11 AM ET Mar 30, 2026
  

  Shanghai Henlius Biotech's serplulimab injection receives CHMP positive opinions for treatment of ESCC, nsNSCLC (HK$69.65, 0.00)

• 07:56 AM ET Mar 27, 2026
  

  EU's CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Hetronifly

• 04:07 PM ET Mar 26, 2026
  

  Eisai and Nuvation Bio announce EMA validation of MAA for taletrectinib in advanced ROS1+ NSCLC ($4.42, 0.00)

• 08:09 AM ET Mar 26, 2026
  

  EISAI to begin enrolling phase 2 study of E2086 in patients with narcolepsy (¥4922.0000, 0)

• 09:47 AM ET Mar 23, 2026
  

  StreetAccount Summary - Private company transactions for the week ended 21-Mar

• 12:46 PM ET Mar 20, 2026
  

  Eisai and Biogen announce results from real-world, long-term treatment persistence with LEQEMBI (lecanemab-irmb) (¥4764.0000, 0)

• 06:40 PM ET Mar 18, 2026
  

  Eisai to suspend administration of Tazverik (tazemetostat) (¥4945.0000, 0)

• 04:41 PM ET Mar 17, 2026
  

  Nuvation Bio to present pivotal IBTROZI (Taletrectinib) data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive NSCLC at AACR 2026 ($4.40, 0.00)

• 12:12 PM ET Mar 16, 2026
  

  StreetAccount Summary - Private company transactions for the week ended 14-Mar

• 04:42 PM ET Mar 13, 2026
  

  HHS/CMS announce full participation by drugmakers in third round of Medicare price negotiations under IRA